| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3037 | Lc0024 | Novel antibiofilm coating, covalently bindng to a titanium implant surface (LC0024-Ti) |
|
| DCC3038 | Lcat Activator A | Novel activator of Lecithin:cholesterol acyltransferase (LCAT) including some familial mutations, by forming a hydrophobic adduct with Cys31 |
|
| DCC3039 | Lcb03-0110 | Novel potent angiogenesis inhibitor, inhibiting VEGFR-2 and JAK/STAT3 signalling in primary cultured human endothelial cells and cancer cells |
|
| DCC3040 | Lcl-peg3-n3 | Novel clickable linker for estrogen receptor degraders |
|
| DCC3041 | Lcrf-0004 | Novel potent and selective RON receptor tyrosine kinase inhibitor |
|
| DCC3042 | Ldc0496 | Novel potent and selective covalent inhibitor of EGFR and Her2 exon20 insertion mutations, exhibiting selectivity over wild type EGFR and within the kinome |
|
| DCC3043 | Ldc7559 | Novel potent inhibitor of the NOX2-dependent oxidative burst in neutrophils by activating the glycolytic enzyme phosphofructokinase-1 liver type (PFKL) and dampening flux through the pentose phosphate pathway |
|
| DCC3044 | Ldc8201 | Novel potent and selective covalent inhibitor of EGFR and Her2 exon20 insertion mutations, exhibiting selectivity over wild type EGFR and within the kinome |
|
| DCC3045 | Ldd-1819 | Novel dual inhibitor of GSK-3β and aurora kinase A, increasing somatic cell plasticity and inhibiting tumorigenicity |
|
| DCC3046 | Ldd970 | Novel Aurora Kinase A Inhibitor |
|
| DCC3047 | Lddn-0003499 | Novel Src family tyrosine kinase inhibitor with anti-inflammatory effects in response to Aß stimulation of microglia |
|
| DCC3048 | Ldha-in-22y | Novel inhibitor of human lactate dehydrogenase A (LDHA) |
|
| DCC3049 | Ldn-0028574 | Novel Inhibitor of SIRT1; Inhibitor of the human MDM2-p53 interaction |
|
| DCC3050 | Ldn-0044878 | Novel PAK3 kinase inhibitor, inhibiting p53-inactivated cancers |
|
| DCC3051 | Ldn-0070977 | Novel inhibitor of PERK stress-dependent eIF2α phosphorylation with no toxicity to the cells |
|
| DCC3052 | Ldn-0130436 | Novel TDP-43::GFP aggregation inhibitor |
|
| DCC3053 | ldn-112006 | Necroptosis inhibitor |
|
| DCC3054 | Ldn-193188 | Novel inhibitor of phosphatidylcholine transfer protein (PC-TP) |
|
| DCC3055 | ldn-193191 | Potent and metabolically stable inhibitor of necroptosis, a regulated caspase-independent cell death pathway |
|
| DCC3056 | ldn-193594 | Novel cdk5/p25 kinase inhibitor |
|
| DCC3057 | Ldn-193665 | Novel potent tau kinase inhibitor, targeting CDK5/p25 and GSK3β |
|
| DCC3058 | ldn-211898 | Potent haspin kinase inhibitor |
|
| DCC3059 | Ldn-213844 | Novel ALK2 inhibitor |
|
| DCC3060 | Ldn-73794 | Competitive LRRK2 kinase inhibitor without affecting the GTPase activity |
|
| DCC3061 | L-dopa-snme3 | Precursor of 6-[18F]Fluoro-L-DOPA used for positron emission tomography (PET) scans. References: http://www.hindawi.com/journals/bmri/2014/674063/ |
|
| DCC3062 | Lds-751 | Nucleic acid binding fluorescent dye |
|
| DCC3063 | Ldt3 Dihydrochloride | Highly potent multi-target antagonists of both alpha1A- and alpha1D-adrenoceptors, and also of 5-HT1A receptors |
|
| DCC3064 | Ldt409 | Novel partial agonist of PPARα and PPARγ, providing distinct and favorable gene activation profiles for the treatment of diabetes and obesity |
|
| DCC3065 | Ldt5 Dihydrochloride | Highly potent multi-target antagonists of both alpha1A- and alpha1D-adrenoceptors, and also of 5-HT1A receptors |
|
| DCC3066 | Ldt8 Dihydrochloride | Highly potent multi-target antagonists of alpha1A- and alpha1D-adrenoceptors, and 5-HT1A receptors |
|
